-
Business
-
Policy & Business
-
-
Federal IT
-
Information Technology
-
-
State & Local
-
State & Local Government
-
-
Defense
-
Defense & Intelligence
-
-
Healthcare
-
Healthcare Policy & IT
-
-
Energy
-
Energy Policy & Technology
-
-
Education
-
Education Policy & Technology
-
FDA spurns Lilly, Boehringer diabetes drug, cites factory problems
Reuters: Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed problems at a facility where it would be made.
The drugmakers, in a joint release on Wednesday, said the U.S. Food and Drug Administration determined that issues at the Boehringer factory in Ingelheim, Germany, need to be resolved before the product could be approved.
Tags
Share
Top Stories
- CMS watchdog suggests targeted approach for hospital wage index increase
- When PHE Ends, Don't Expect Grace Period From CMS
- Lawmakers left hospital, insurer contract guardrails out of year-end proposal
- CMS creates direct contracting model to serve individuals dually eligible for Medicare and Medicaid
- Local Health Departments Are Understaffed. Would Biden’s ‘Public Health Jobs Corps’ Help?
- HHS wants to boost interoperability for Medicaid and CHIP
- CDC is giving $227 million for COVID-19 vaccine preparedness and tracking
- ‘We want them infected’: Trump appointee demanded ‘herd immunity’ strategy, emails reveal
- CMS Updates Part B Payment Information for COVID-19 Treatments
- FDA finds Moderna vaccine 95% effective
- FDA Analysis Of Pfizer COVID-19 Vaccine Finds It Effective And Safe
- High court will hear appeal over Medicaid work requirements
- Bipartisan Cadre of Lawmakers Call for Permanent Telehealth Expansion
- Biden Will Issue Mask Mandate for Federal Buildings
- CMS unveils highly anticipated geographic direct-contracting model
- Pushed to rush, FDA head says feds will get vaccine 'right'
Whitepapers & Special Reports
i360Gov Newsletters
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe NowAlso in Healthcare Policy & IT
About
i360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Contact Us
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
Newsletters
Copyright © 2009-2025 i360Communications, LLC.